key: cord-0870573-hzx0apjj
authors: Raiker, R.; Pakhchanian, H.; Hussain, A.; Deng, M.
title: Outcomes of COVID‐19 in patients with skin cancer
date: 2021-06-17
journal: Br J Dermatol
DOI: 10.1111/bjd.20386
sha: 93c4e7040364e9af30f989630773881d717d2f54
doc_id: 870573
cord_uid: hzx0apjj

The effect of skin cancer diagnosis on the risk of adverse outcomes from COVID-19 remains unknown. Few studies have shown cancer patients with COVID-19 have higher rates of mortality and hospitalizations compared to those without cancer, perhaps due to a combination of delayed diagnosis and pre-existing comorbidities from chemotherapy and radiation treatments.1.

In total, 455 505 patients with COVID-19 were identified (skin cancer, n = 7681; no skin cancer, n = 447 824). Before PSM, the skin cancer cohort was older [mean (SD) age 69 (14) vs. 47 (19) years; P < 0Á001] and there was a higher proportion of males (52% vs. 44%; P < 0Á001), people with white skin (91% vs. 60%; P < 0Á001) and comorbidities. After PSM, two well-matched cohorts of 7663 patients were created. Outcomes before and after PSM are given in Table S1 (see Supporting Information). After PSM, the skin cancer group had improved outcomes than controls regarding mortality (4Á5% vs. 5Á7%; P < 0Á001), mechanical ventilation (3Á8% vs. 4Á8%; P = 0Á002), hospitalization (21% vs. 28%; P < 0Á001), severe COVID (6Á7% vs. 8Á4%; P < 0Á001) and ARDS (1Á8% vs. 2Á3%; P = 0Á023), with no differences seen between the groups with regard to sepsis. In matched subgroup analysis, patients with melanoma and SCC had decreased hospitalization rates vs. controls [21% vs. 25% (P = 0Á002) and 28% vs. 32% (P = 0Á001), respectively]. There were no differences in matched analyses for all other outcomes between the melanoma and SCC cohorts. In the matched BCC cohorts, patients with BCC had improved outcomes vs. controls with regard to mortality (4Á0% vs. 5Á6%; P < 0Á001), mechanical ventilation (3Á2% vs. 4Á9%; P < 0Á001), hospitalization (18% vs. 27%; P < 0Á001), severe COVID (5Á8% vs. 8Á4%; P < 0Á001), ARDS (1Á5% vs. 2Á2%; P = 0Á012) and sepsis (4Á7% vs. 5Á8%; P = 0Á028).

Until now, the information on the effect of skin cancer on COVID-19 outcomes has been scant. Matching revealed that the skin cancer cohort demonstrated a significantly reduced risk of adverse outcomes, which was most pronounced in the BCC subgroup. While the pathophysiological basis of this finding is unclear, research has shown increased mortality in patients with COVID-19 with low serum 25-hydroxyvitamin D levels. 4 Therefore, we hypothesize that patients with BCC have higher vitamin D levels, which may protect against severe COVID-19 outcomes. While serum 25-hydroxyvitamin D has been positively associated with melanoma and keratinocyte carcinoma, particularly BCC, 5, 6 there may be other residual confounders in patients with COVID-19 with SCC and melanoma that were impossible to elucidate from the data, such as duration of immunosuppression, severity of chronic skin inflammation and genetic make-up, which could have contributed to the findings of the given outcomes. A limitation of this study is that because vitamin D levels are not routinely assessed in either in-or outpatients, there were incomplete records of vitamin D levels in the database and so pre-existing levels could not be examined. Other limitations include

The COVID-19 pandemic and its impact on the cardio-oncology population

Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis

Impact of obesity on outcomes of patients with coronavirus disease 2019 in the United States: a multicenter electronic health records network study

Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers

25-hydroxyvitamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose-response meta-analysis of prospective studies

Association of prediagnostic serum vitamin D levels with the development of basal cell carcinoma